Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling

Dodds EC, Lawsaon W, Robinson R, 1938 Estrogenic activity of certain synthetic compounds. Nature 141247–141248. Smith OW, Smith GBS, Hurwitz D, 1946 Increased excretion of pregnanediol in pregnancy from diethyl-stilbestrol with special reference to the prevention of late pregnancy accidents. Med Rec Ann 40: 1669–1671. Dieckmann WJ, Davis Me, Rynkiewicz lM, Pottinger RE, Gabbe SG, 1999 Does the administration of diethylstilbestrol during pregnancy have therapeutic value 1953? Am J Obstet Gynecol 66:1062–1081. Herbst AL, Ulfelder H, Poskanzer DC, 1971 Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284: 878–881. Melnick S, Cole P, Anderson D, Herbst A, 1987 Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 316: 514–516. Herbst AL, 2000 Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES). Gynecol Oncol 76: 147–156. Mittendorf R, 1995 Teratogen update: carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. Teratology 51: 435–445. Kaufman RH, Adam E, Hatch EE, et al, 2000 Continued follow-up of pregnancy outcomes in diethylstilbestrolexposed offspring. Obstet Gynecol 96: 483–489. Giusti RM, Iwamoto K, Hatch EE, 1995 Diethylstilbestrol revisited: a review of the long-term health effects. Ann Intern Med 122: 778–788. Marselos M, Tomatis L, 1992 Diethylstilboestrol: I, Pharmacology, Toxicology and carcinogenicity in humans. Eur J Cancer 28A: 1182–1189. Newbold RR, McLachlan JA, 1982 Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol. Cancer Res 42: 2003–2011. Marselos M, Tomatis L, 1992 Diethylstilboestrol: II, pharmacology, toxicology and carcinogenicity in experimental animals. Eur J Cancer 29A: 149–55. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O, 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 90: 11162–11166. Krege JH, Hodgin JB, Couse JF, et al, 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 95: 15677–15682. Couse JF, Dixon D, Yates M, et al, 2001 Estrogen receptor-alpha knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbestrol exposure on the female reproductive tract. Dev Biol 238: 224–238. Couse JF, Korach KS, 2004 Estrogen receptor-alpha mediates the detrimental effects of neonatal diethylstilbestrol (DES) exposure in the murine reproductive tract. Toxicology 205: 55–63. Prins GS, Birch L, Couse JF, Choi I, Katzenellenbogen B, Korach KS, 2001 Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice. Cancer Res 61: 6089–6097. Singh J, Handelsman DJ, 1999 Morphometric studies of neonatal estrogen imprinting in the mature mouse prostate. J Endocrinol 162: 39–48. Dollé P, Izpisúa-Belmonte JC, Brown JM, Tickle C, Duboule D, 1991 HOX-4 genes and the morphogenesis of mammalian genitalia. Genes Dev 5: 1767–1767. Hsieh-Li HM, Witte DP, Weinstein M, et al, 1995 Hoxa 11 structure, extensive antisense transcription, and function in male and female fertility. Development 121: 1373–1385. Satokata I, Benson G, Maas R, 1995 Sexually dimorphic sterility phenotypes in Hoxa10-deficient mice. Nature 374: 460–463. Miller C, Degenhardt K, Sassoon DA, 1998 Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis. Nat Genet 20: 228–230. Parr BA, McMahon AP, 1998 Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a. Nature 395: 707–710. Block K, Kardana A, Igarashi P, Taylor HS, 2000 In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system. Faseb J 14: 1101–1108. Ma L, Benson GV, Lim H, Dey SK, Maas RL, 1998 Abdominal B (AbdB) Hoxa genes: regulation in adult uterus by estrogen and progesterone and repression in mullerian duct by the synthetic estrogen diethylstilbestrol (DES). Dev Biol 197: 141–154. Li S, Washburn KA, Moore R, et al, 1997 Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus. Cancer Res 57: 4356–4359. Li S, Hansman R, Newbold R, Davis B, McLachlan JA, Barrett JC, 2003 Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus. Mol Carcinog 38: 78–84. Li S, Ma L, Chiang T, et al, 2001 Promoter CpG meth-ylation of Hox-a10 and Hox-a11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure. Mol Carcinog 32: 213–219. Akbas GE, Song J, Taylor HS, 2004 A HOXA10 estrogen response element (ere) is differentially regulated by 17 beta-estradiol and diethylstilbestrol (DES). J Mol Biol 340: 1013–1023. Moutsatsou P, 2007 The spectrum of phytoestrogens in nature: our knowledge is expanding. Hormones (Athens) 6: 173–193. Santell RC, Chang YC, Nair MG, Helferich WG, 1997 Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in rats. J Nutr 127: 263–269. Hsieh CY, Santell RC, Haslam SZ, Helferich WG, 1998 Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 58: 3833–3838. Collins BM, McLachlan JA, Arnold SF, 1997 The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 62: 365–372. Akiyama T, Ishida J, Nakagawa S, et al, 1987 Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592–5595. Hilakivi-Clarke L, Onojafe I, Raygada M, et al, 1999 Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br J Cancer 80: 1682–1688. Lamartiniere CA, Zhang JX, Cotroneo MS, 1998 Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr 68(6 Suppl): 1400S–1405S. Hilakivi-Clarke L, Cho E, Onojafe I, Raygada M, Clarke R, 1999 Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol Rep 6: 1089–1095. Bradbury RB, White DE, 1954 Estrogens and related substances in plants. Vitam Horm 12207-12233. Setchell KD, Gosselin SJ, Welsh MB, et al, 1987 Dietary estrogens—a probable cause of infertility and liver disease in captive cheetahs. Gastroenterology 93: 225–233. Newbold RR, Banks EP, Bullock B, Jefferson WN, 2001 Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer Res 61: 4325–4328. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr., 1998 Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68: Suppl 6: 1375–1379. Cruz ML, Wong WW, Mimouni F, et al, 1994 Effects of infant nutrition on cholesterol synthesis rates. Pediatr Res 35: 135–140. Setchell KD, Zimmer-Nechemias l, Cai J, Heubi Je, 1997 Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 350: 23–27. Cassidy A, Bingham S, Setchell KD, 1994 Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60: 333–340. Kuiper GG, Lemmen JG, Carlsson B, et al, 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252–4263. Mueller SO, Simon S, Chaek, Metzler M, Korach CS, 2004 Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80: 14–25. Jefferson WN, Padilla-Banks E, Clark G, Newbold RR, 2002 Assessing estrogenic activity of phytochemicals using transcriptional activation and immature mouse uterotrophic responses. J Chromatogr B Analyt Technol Biomed Life Sci 777: 179–189. Klotz DM, Hewitt SC, Korach KS, Diaugustine RP, 2000 Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha. Endocrinology 141: 3430–3439. Jefferson WN, Couse JF, Padilla-Banks E, Korach KS, Newbold RR, 2002 Neonatal exposure to genistein induces estrogen receptor (ER)alpha expression and multioocyte follicles in the maturing mouse ovary: evidence for ERbeta-mediated and nonestrogenic actions. Biol Reprod 67: 1285–1296. Johanson G, 2000 Toxicity review of ethylene glycol monomethyl ether and its acetate ester. Crit Rev Toxicol 30: 307–345. Chapin RE, Dutton SL, Ross MD, Lamb JC 4th, 1985 Effects of ethylene glycol monomethyl ether (EGME) on mating performance and epididymal sperm parameters in F344 rats. Fundam Appl Toxicol 5: 182–189. Brinkworth MH, Weinbauer GF, Schlatt S, Nieschlag E, 1995 Identification of male germ cells undergoing apoptosis in adult rats. J Reprod Fertil 105: 25–33. Foster PM, Creasy DM, Foster JR, Gray TJ, 1984 Testicular toxicity produced by ethylene glycol monomethyl and monoethyl ethers in the rat. Environ Health Perspect 57207–57217. Nagano K, Nakayama E, Oobayashi H, et al, 1981 Embryotoxic effects of ethylene glycol monomethyl ether in mice. Toxicology 20: 335–343. Correa A, Gray RH, Cohen R, et al, 1996 Ethylene glycol ethers and risks of spontaneous abortion and subfertility. Am J Epidemiol 143: 707–717. El-Zein RA, Abdel-Rahman SZ, Morris DL, Legator MS, 2002 Exposure to ethylene glycol monomethyl either: clinical and cytogenetic findings. Arch Environ Health 57: 371–376. Davis BJ, Almekinder JL, Flagler N, Travlos G, Wilson R, Maronpot RR, 1997 Ovarian luteal cell toxicity of ethylene glycol monomethyl ether and methoxy acetic acid in vivo and in vitro. Toxicol Appl Pharmacol 142: 328–337. Rao PN, 1971 Preparation of 9-alpha,11-xi-tritiated 17-alpha-ethynylestradiol, mestranol, estradiol-alpha-17-beta, and norethindrone. Steroids 18: 219–229. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä W, 1993 Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329: 1383–1388. O’Donovan C, Kusumakar V, Graves GR, Bird DC, 2002 Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 63: 322–330. Löfgren E, Mikkonen K, Tolonen U, et al, 2007 Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication. Epilepsy Behav 10: 77–83. Jansen MS, Nagel SC, Miranda PJ, Lobenhofer EK, Afshari CA, McDonnell DP, 2004 Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc Natl Acad Sci U S A 101: 7199–7204. Göttlicher M, Minucci S, Zhu P, et al, 2001 Valproic acid defines a novel class of HDac inhibitors inducing differentiation of transformed cells. Embo J 20: 6969–6978. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS, 2001 Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734–36741. Sealy L, Chalkley R, 1978 The effect of sodium butyrate on histone modification. Cell 14: 115–121. Boffa LC, Vidali G, Mann RS, Allfrey VG, 1978 Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253: 3364–3366. Henley DV, Mueller S, Korach KS, 2009 The short-chain fatty acid methoxyacetic acid dirsupts endogenous estrogen receptor alpha mediated signaling. Environ Health Perspect. Henley DV, Lipson N, Korach KS, Bloch CA, 2007 Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med 356: 479–485. Braunstein GD, 1993 Gynecomastia. N Engl J Med 328: 490–495. Einav-Bachar R, Phillip M, Aurbach-Klipper Y, Lazar L, 2004 Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol (Oxf) 61: 55–60. Descamps H, Chaussain JL, Job JC, 1985 [Gynecomastia in boys before puberty]. Arch Fr Pediatr 42: 87–89. Nielsen JB, 2008 What you see may not always be what you get—bioavailability and extrapolation from in vitro tests. Toxicol In Vitro 22: 1038–1042. Wilson VS, Bobseine K, Lambright CR, Gray LE Jr., 2002 A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol Sci 66: 69–81. Perry NS, Houghton PJ, Sampson J, et al, 2001 In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of alzheimer’s disease. J Pharm Pharmacol 53: 1347–1356. Tabanca N, Khan SI, Bedir E, et al, 2004 Estrogenic activity of isolated compounds and essential oils of Pimpinella species from Turkey, evaluated using a recombinant yeast screen. Planta Med 70: 728–735. Howes MJ, Houghton PJ, Barlow DJ, Pocock VJ, Milligan SR, 2002 Assessment of estrogenic activity in some common essential oil constituents. J Pharm Pharmacol 54: 1521–1528. Dhar SK, 1995 Anti-fertility activity and hormonal profile of trans-anethole in rats. Indian J Physiol Pharmacol 39: 63–67. Geldof AA, Engel C, Rao BR, 1992 Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. Urol Res 20: 139–144. Chung BH, Lee Hy, Lee JS, Young CY, 2006 Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 236: 222–228.